Real-World look at oral drug aiming to keep blood cancer at bay
NCT ID NCT06565975
Summary
This study collected real-world information from 112 patients in France with acute myeloid leukemia (AML) who were in remission. It aimed to understand how well an oral maintenance drug called azacitidine works to prevent the cancer from coming back and to describe the patients' experiences and outcomes. The goal was to gather practical evidence on how this treatment is used and its effectiveness in everyday clinical practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kappa Sante
Paris, 75002, France
Conditions
Explore the condition pages connected to this study.